GlassScriptPhysician profile
Preet Vaidyanathan
NPI 1447408224
$8,311.02
in general payments reported to CMS, 2019-2025
30 companies · $2,141 in 2025
The $2,141 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $1,622 · 2023: $2,088 · 2024: $1,489 · 2025: $2,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,532 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,532.01 |
| Education | $185.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,313.07 | 2022-2025 | Tremfya |
| Pfizer INC. | $996.64 | 2021-2025 | |
| Abbvie INC. | $956.44 | 2022-2025 | |
| Leo Pharma INC. | $674.45 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $516.98 | 2021-2025 | |
| Galderma Laboratories, L.P. | $452.13 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Arcutis Biotherapeutics, INC. | $387.13 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $353.38 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $295.51 | 2022-2025 | Dupixent |
| Amgen INC. | $256.41 | 2022-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $252.60 | 2021-2023 | |
| Incyte Corporation | $240.98 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $233.31 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $203.31 | 2023-2024 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $174.47 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $154.54 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $117.91 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.44 | 2023-2024 | Spevigo |
| Ucb, INC. | $93.01 | 2021-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $89.92 | 2021 | |
| Sebela Pharmaceuticals INC. | $86.27 | 2022-2023 | Naftin |
| Sun Pharmaceutical Industries INC. | $84.19 | 2021-2023 | Ilumya |
| Organon LLC | $81.18 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $41.07 | 2025 | Nuzyra |
| Revance Therapeutics, INC. | $36.57 | 2024 | Daxxify |
| Verrica Pharmaceuticals INC. | $28.55 | 2024 | Ycanth |
| Celltrion USA INC. | $26.97 | 2023 | Yuflyma |
| Journey Medical Corporation | $24.60 | 2023 | |
| Almirall LLC | $17.06 | 2025 | Klisyri |
| Kyowa Kirin, INC. | $15.93 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preet Vaidyanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.